First Tracks Biotherapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, below.
EXHIBIT INDEX
| Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date | Filed Herewith |
| 2.1†‡ | Separation and Distribution Agreement, dated as of April 20, 2026, by and between AnaptysBio, Inc. and First Tracks Biotherapeutics, Inc. | 8-K | 001-43177 | 2.1 | April 20, 2026 | |
| 10.1† | Transition Services Agreement, dated as of April 20, 2026, by and between AnaptysBio, Inc. and First Tracks Biotherapeutics, Inc. | 8-K | 001-43177 | 10.1 | April 20, 2026 | |
| 10.2†‡ | Registration Rights Agreement, dated as of April 20, 2026, by and among the Company and the Investors party thereto. | 8-K | 001-43177 | 10.2 | April 20, 2026 | |
| 10.3*+ | Employment Agreement, effective April 20, 2026, by and between the Registrant and Daniel Faga. | 10-Q | 001-43177 | 10.3 | May 14, 2026 | |
| 10.4*+ | Employment Agreement, effective April 20, 2026, by and between the Registrant and Paul Lizzul. | 10-Q | 001-43177 | 10.4 | May 14, 2026 | |
| 10.5*+ | Employment Agreement, effective April 20, 2026, by and between the Registrant and Ajim Tamboli. | 10-Q | 001-43177 | 10.5 | May 14, 2026 | |
| 10.6*+ | Employment Agreement, effective April 20, 2026, by and between the Registrant and Benjamin Stone. | 10-Q | 001-43177 | 10.6 | May 14, 2026 | |
| 10.7†+‡ | License Agreement, dated November 24, 2023, by and between the Registrant and Centessa Pharmaceuticals (UK) Limited. | 10-Q | 001-43177 | 10.7 | May 14, 2026 | |
| 10.8†+‡ | Amendment No. 1 to License Agreement, dated April 9, 2024, by and between the Registrant and Centessa Pharmaceuticals (UK) Limited. | 10-Q | 001-43177 | 10.8 | May 14, 2026 | |
| 10.9 | Wateridge Sublease Agreement | X | ||||
| 10.10 | Form of Indemnity Agreement. | X | ||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 101.INS | Inline XBRL Report Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | |||||
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL document and contained in Exhibit 101) | |||||
†Certain portions of this exhibit have been redacted pursuant to Item 601(b)(2)(ii) and Item 601(b)(10)(iv) of Regulation S-K, as applicable. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon its request.
- Executive compensation plan or agreement.
- Certain portions of this exhibit have been redacted in accordance with Item 601(a)(6) of Regulation S-K.
‡ The schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the Commission upon its request.
** This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.